Borderline

Art Show to Highlight the Lived Experience of Borderline Personality Disorder

Retrieved on: 
Monday, October 24, 2022

NEW YORK, Oct. 24, 2022 /PRNewswire/ -- Kristyn is one of 1.6% in the U. S. population affected by borderline personality disorder (BPD) a highly stigmatized mental illness contributing to the increase in self-harm and suicidality in our society. Up to 75% of people diagnosed with BPD experience a suicide attempt, and sadly, 10% succeed.

Key Points: 
  • Up to 75% of people diagnosed with BPD experience a suicide attempt, and sadly, 10% succeed.
  • It seeks to change public opinion of this disorder by highlighting the severity of its symptoms as expressed by people with lived experience through art in a new ground-breaking exhibit.
  • All participants identify with lived experience as either those with the disorder, or family members impacted by it.
  • Sponsors for this event include New York-Presbyterian Hospital, the Francesco and Mary Giambelli Foundation, McLean Hospital, Silver Hill Hospital and the National Education Alliance on Borderline Personality Disorder.

Peer Organization Launches National Conference for Borderline Personality Disorder

Retrieved on: 
Friday, May 14, 2021

b'GARDEN CITY, N.Y., May 14, 2021 /PRNewswire/ -- Emotions Matter, Inc. is pleased to announce it will be hosting its first ever Virtual Conference for Borderline Personality Disorder (BPD).\n"BPD is the most stigmatized mental illness.

Key Points: 
  • b'GARDEN CITY, N.Y., May 14, 2021 /PRNewswire/ -- Emotions Matter, Inc. is pleased to announce it will be hosting its first ever Virtual Conference for Borderline Personality Disorder (BPD).\n"BPD is the most stigmatized mental illness.
  • I am so excited to be part of this ground-breaking conference.
  • I am so excited to be part of the ground-breaking conference with others from around the country to change attitudes and promote recovery."
  • This groundbreaking event will include:\nProminent speakers and attendees from across the nation.\nEmotions Matters Mission Statement:To connect and empower those impacted by Borderline Personality Disorder (BPD) to raise awareness about BPD and advocate for better mental health care.

ORYZON to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

Retrieved on: 
Wednesday, November 11, 2020

In accordance with the embargo terms and conditions for presentation at ASH, data will be released on the same day as the e-poster.

Key Points: 
  • In accordance with the embargo terms and conditions for presentation at ASH, data will be released on the same day as the e-poster.
  • Dr. Carlos Buesa, Oryzons CEO, will present at Jefferies 2020 Virtual London Healthcare Conference, to be held on November 17-19.
  • Additionally, the company will participate in the virtual Borderline Personality Disorder Day organized by the Spanish BPD Association, AMAI-TLP on November 20th.
  • Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics.